Childhood mixed connective tissue disease at disease onset: Evidence from a systematic review

Alberto Terminiello,Edoardo Marrani,Ilaria Pagnini,Ilaria Maccora,Valerio Maniscalco,Sarah Abu Rumeileh,Maria Vincenza Mastrolia,Gabriele Simonini
DOI: https://doi.org/10.1016/j.autrev.2023.103513
IF: 17.39
2024-01-08
Autoimmunity Reviews
Abstract:Objective Childhood Mixed Connective Tissue Disease (cMCTD) is the rarest pediatric connective tissue disease that includes features of systemic lupus erythematosus, polymyositis/dermatomyositis, juvenile idiopathic arthritis, and systemic sclerosis, identified by Sharp in 1972 and whose diagnosis remains challenging. This systematic review aims to identify clinical features at the onset of cMCTD and manifestations not currently included into the available diagnostic criteria. Methods A systematic literature review was performed in accordance with PRISMA guidelines 2020 using bibliographic databases: MEDLINE via PubMed and EMBASE. Eligibility criteria: patients diagnosed with MCTD with onset before 18 years. Studies included: registries, retrospective and prospective cohort studies, case series and reports with analysis of data on signs and symptoms of presentation. Results 39 articles were included (215 subjects, 82.5% female), mean age of 141 months (± 41 months DS, range 2.5–204). The most used criteria for the diagnosis of MCTD were the Kasukawa criteria (54.5%). The clinical manifestations described at onset were Raynaud's phenomenon (69.7%), arthritis (60.9%), muscular involvement (53.5%), dermatological signs (39.5%), swollen fingers or hands (29.3%), arthralgias (25.6%), fever (22.3%), lung involvement (14.4%), sclerodactily (13.5%), lymphadenopathy (10.7%) serositis (10.2%), esophageal involvement (6.9%), nervous system involvement (6.9%), xeroftalmia (3.7%), xerostomia (3.7%), hepatosplenomegaly (2.8%), cardiac involvement (2.8%), hepatitis (2.3%), parotiditis (2.3%), Hashimoto's thyroiditis (0.9%), ocular involvement (0.9%). Conclusions The data from this systematic review suggest great heterogeneity of the clinical presentation of cMCTD for which there are no validated diagnostic criteria that may suggest a new diagnostic approach to allow earlier or more accurate diagnosis in the future.
immunology
What problem does this paper attempt to address?